ADA/EASD position statement of the treatment of type 2 diabetes: Reply to Rodbard HW and Jellinger PS [letter], Scheen AJ [letter] and Ceriello A, Gallo M, Gentile S et al [letter].
第一作者:
D R,Matthews
第一单位:
Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Headington, Oxford, OX3 7LJ, UK. david.matthews@ocdem.ox.ac.uk.;National Institute for Health Research (NIHR), Oxford Biomedical Research Centre, Oxford, UK. david.matthews@ocdem.ox.ac.uk.;Harris Manchester College, University of Oxford, Mansfield Road, Oxford, UK. david.matthews@ocdem.ox.ac.uk.
作者:
医学主题词
算法(Algorithms);糖尿病, 2型(Diabetes Mellitus, Type 2);二肽基肽酶Ⅳ抑制剂(Dipeptidyl-Peptidase IV Inhibitors);人类(Humans);降血糖药(Hypoglycemic Agents);二甲双胍(Metformin);学会, 医学(Societies, Medical)
DOI
10.1007/s00125-012-2669-z
PMID
22854891
发布时间
2021-10-21
- 浏览10
Diabetologia
2856-2857页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



